

Hiroaki Iwamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8903957/publications.pdf>

Version: 2024-02-01

46
papers

589
citations

758635

12
h-index

676716

22
g-index

46
all docs

46
docs citations

46
times ranked

798
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis. <i>Oncotarget</i> , 2017, 8, 9739-9751.	0.8	98
2	Tumor necrosis factor α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation. <i>Cancer Science</i> , 2018, 109, 1524-1531.	1.7	72
3	CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. <i>Cancer Science</i> , 2019, 110, 279-288.	1.7	40
4	Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer. <i>Oncotarget</i> , 2016, 7, 8389-8398.	0.8	34
5	Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis. <i>Cancers</i> , 2020, 12, 89.	1.7	33
6	CC motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment. <i>Cancer Science</i> , 2018, 109, 724-731.	1.7	29
7	Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells. <i>Prostate</i> , 2019, 79, 468-479.	1.2	29
8	Intraoperative hypotension caused by oral administration of 5 α -aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer. <i>International Journal of Urology</i> , 2019, 26, 1064-1068.	0.5	28
9	Is the C-C Motif Ligand 2 "C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9328.	1.8	27
10	Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. <i>Oncotarget</i> , 2018, 9, 16185-16196.	0.8	26
11	Anti-proliferative and anti-migratory properties of coffee diterpenes kahweol acetate and cafestol in human renal cancer cells. <i>Scientific Reports</i> , 2021, 11, 675.	1.6	16
12	Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer. <i>Prostate</i> , 2021, 81, 72-80.	1.2	15
13	Factors Associated With Treatment Satisfaction After Robot-assisted Radical Prostatectomy. <i>Anticancer Research</i> , 2019, 39, 6339-6346.	0.5	9
14	Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital. <i>Anticancer Research</i> , 2019, 39, 2607-2614.	0.5	9
15	Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy. <i>In Vivo</i> , 2021, 35, 1703-1709.	0.6	9
16	Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 2291-2296.	0.5	8
17	A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells. <i>Prostate</i> , 2021, 81, 295-306.	1.2	7
18	The Impact of Hypertension on the Clinicopathological Outcome and Progression of Renal Cell Carcinoma. <i>Anticancer Research</i> , 2020, 40, 4087-4093.	0.5	7

#	ARTICLE	IF	CITATIONS
19	Novel Prevention Procedure for Inguinal Hernia after Robot-Assisted Radical Prostatectomy: Results from a Prospective Randomized Trial. <i>Journal of Endourology</i> , 2019, 33, 302-308.	1.1	6
20	Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer. <i>In Vivo</i> , 2021, 35, 1247-1252.	0.6	6
21	Treatment Strategies for High-Risk Localized and Locally Advanced and Oligometastatic Prostate Cancer. <i>Cancers</i> , 2021, 13, 4470.	1.7	6
22	Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor. <i>In Vivo</i> , 2018, 32, 899-903.	0.6	5
23	Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 4291-4297.	0.5	5
24	Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells. <i>Anticancer Research</i> , 2018, 38, 2045-2055.	0.5	5
25	Three-dimensional morphological analysis of spermatogenesis in aged mouse testes. <i>Scientific Reports</i> , 2021, 11, 23007.	1.6	5
26	Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 770067.	1.3	5
27	Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer. <i>Cancers</i> , 2022, 14, 1803.	1.7	5
28	Metastatic urachal cancer treated effectively with gemcitabine/cisplatin combination chemotherapy and radiotherapy: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 139-142.	0.4	4
29	Effectiveness of Synthetic Polymer-coated Peripherally Inserted Central Catheter in Patients With Advanced Cancer. <i>In Vivo</i> , 2019, 33, 877-880.	0.6	4
30	A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age. <i>Asian Journal of Andrology</i> , 2021, 23, 36.	0.8	4
31	Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review. <i>World Journal of Men's Health</i> , 2020, 38, 132.	1.7	4
32	Variations in photodynamic diagnosis for bladder cancer due to the quality of endoscopic equipment. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 37, 102628.	1.3	4
33	Impact of Pelvic Anatomical Changes Caused by Radical Prostatectomy. <i>Cancers</i> , 2022, 14, 3050.	1.7	4
34	Decreased febrile neutropenia during inpatient chemotherapy for urologic cancer during coronavirus disease 2019 pandemic. <i>Cancer Science</i> , 2023, 114, 201-210.	1.7	4
35	Examination of Necessity for Pelvic Drain Placement After Robot-assisted Radical Prostatectomy. <i>In Vivo</i> , 2021, 35, 2895-2899.	0.6	3
36	The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer. <i>Anticancer Research</i> , 2020, 40, 1141-1146.	0.5	3

#	ARTICLE	IF	CITATIONS
37	Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study. Japanese Journal of Clinical Oncology, 0, , .	0.6	3
38	Significance of metastasectomy for urothelial carcinoma. Annals of Oncology, 2015, 26, vii144.	0.6	2
39	Palonosetron on Days 1 and 5 <i>Versus</i> Granisetron Daily (Days 1-5) in Germ Cell Tumour Therapy. In Vivo, 2019, 33, 643-647.	0.6	2
40	Reply to Comment on "Kadomoto, S. et al. Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis"•Cancers 2020 12, 89. Cancers, 2020, 12, 354.	1.7	2
41	Incidences of visceral metastases from prostate cancer increase after progression of castration-resistant status.. Journal of Clinical Oncology, 2018, 36, 291-291.	0.8	2
42	MP66-15 TGF- β 1 AND CCL2 AS POTENTIAL BIOMARKERS AND TREATMENT TARGETS FOR PROSTATE CANCER BONE METASTASIS. Journal of Urology, 2016, 195, .	0.2	0
43	Test clamp procedure in robot-assisted partial nephrectomy: is it a safe procedure?. Journal of Robotic Surgery, 2021, , 1.	1.0	0
44	Clinical Outcomes of Three or More Courses of First-line Chemotherapy for Metastatic Urothelial Carcinoma. Cancer Diagnosis & Prognosis, 2021, 1, 459-461.	0.3	0
45	Treatment at an Inexperienced Center Suggests Worse Prognosis of Metastatic Germ Cell Tumors. Cancer Diagnosis & Prognosis, 2021, 1, 13-17.	0.3	0
46	Carbon dioxide gas embolism during robot-assisted laparoscopic partial nephrectomy. IJU Case Reports, 0, , .	0.1	0